AU2012335663B2 - Method of treating a proliferative disease - Google Patents

Method of treating a proliferative disease Download PDF

Info

Publication number
AU2012335663B2
AU2012335663B2 AU2012335663A AU2012335663A AU2012335663B2 AU 2012335663 B2 AU2012335663 B2 AU 2012335663B2 AU 2012335663 A AU2012335663 A AU 2012335663A AU 2012335663 A AU2012335663 A AU 2012335663A AU 2012335663 B2 AU2012335663 B2 AU 2012335663B2
Authority
AU
Australia
Prior art keywords
braf
treatment
braf inhibitor
weeks
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012335663A
Other languages
English (en)
Other versions
AU2012335663A1 (en
Inventor
Darrin Stuart
Meghna Das THAKUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AU2012335663A1 publication Critical patent/AU2012335663A1/en
Application granted granted Critical
Publication of AU2012335663B2 publication Critical patent/AU2012335663B2/en
Assigned to ARRAY BIOPHARMA, INC. reassignment ARRAY BIOPHARMA, INC. Request for Assignment Assignors: NOVARTIS AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012335663A 2011-11-11 2012-11-09 Method of treating a proliferative disease Active AU2012335663B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558619P 2011-11-11 2011-11-11
US61/558,619 2011-11-11
PCT/US2012/064269 WO2013070996A1 (en) 2011-11-11 2012-11-09 Method of treating a proliferative disease

Publications (2)

Publication Number Publication Date
AU2012335663A1 AU2012335663A1 (en) 2014-05-29
AU2012335663B2 true AU2012335663B2 (en) 2015-12-24

Family

ID=47279036

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012335663A Active AU2012335663B2 (en) 2011-11-11 2012-11-09 Method of treating a proliferative disease

Country Status (10)

Country Link
US (1) US11007194B2 (enExample)
EP (1) EP2776037B1 (enExample)
JP (1) JP6150813B2 (enExample)
CN (2) CN103917236A (enExample)
AU (1) AU2012335663B2 (enExample)
BR (1) BR112014011223A8 (enExample)
CA (1) CA2855243C (enExample)
MX (1) MX354725B (enExample)
RU (1) RU2622015C2 (enExample)
WO (1) WO2013070996A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2882440B1 (en) * 2012-08-07 2019-02-27 Novartis AG Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX387795B (es) * 2016-06-03 2025-03-19 Array Biopharma Inc Combinaciones farmaceuticas.
US11590133B2 (en) * 2016-12-11 2023-02-28 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of BRAF mutant cancers
WO2020011141A1 (zh) * 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CN114929279A (zh) * 2020-01-07 2022-08-19 锐新医药公司 Shp2抑制剂给药和治疗癌症的方法
US12303509B2 (en) 2020-06-09 2025-05-20 Pfizer Inc. Compounds for the treatment of BRAF-associated diseases and disorders
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd International Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
ES3035530T3 (en) 2023-03-09 2025-09-04 Minneamrita Therapeutics Llc Drug combination for the treatment of stomach cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
HUP0001880A3 (en) 1997-05-22 2002-03-28 G D Searle & Co Chicago Substituted pyrazoles as p38 kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ES2295428T3 (es) 2001-10-25 2008-04-16 Novartis Ag Combinaciones que comprenden un inhibidor selectivo de ciclooxigenasa-2.
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
EP1682181A2 (en) 2003-09-23 2006-07-26 Novartis AG Combination of a vegf receptor inhibitor with a chemotherapeutic agent
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
WO2005068452A1 (en) 2004-01-09 2005-07-28 Novartis Ag Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
CN1960988B (zh) 2004-06-10 2012-01-25 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
RU2007138264A (ru) 2005-03-17 2009-09-10 Новартис АГ (CH) N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF
US20070099856A1 (en) * 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
EP1934185A1 (en) 2005-08-12 2008-06-25 Synta Pharmaceuticals Corporation Pyrazole compounds that modulate hsp90 activity
CA2619035A1 (en) 2005-08-22 2007-03-01 Novartis Ag Pharmaceutical compositions
EP1917258A2 (en) 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
PE20070427A1 (es) 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
EP2024353A2 (en) 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
EP2004165A2 (en) 2006-04-05 2008-12-24 Novartis Pharma AG Synergistic combinations of anticancer agents for treating cancer
US7501430B2 (en) 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
CN103739595A (zh) 2006-10-02 2014-04-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2008045627A2 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
US20100069458A1 (en) 2007-02-15 2010-03-18 Peter Wisdom Atadja Combination of lbh589 with other therapeutic agents for treating cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
CN101815712A (zh) 2007-08-01 2010-08-25 辉瑞有限公司 吡唑化合物及其作为raf抑制剂的用途
CN101827584A (zh) 2007-10-19 2010-09-08 雅培股份有限两合公司 N-芳基脲基药物的固态分散体产品
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
EA201001456A1 (ru) 2008-03-21 2011-06-30 Новартис Аг Новые гетероциклические соединения и их применение
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
AU2009273197B2 (en) 2008-07-24 2014-01-16 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
MX2011003292A (es) 2008-09-29 2011-04-21 Boehringer Ingelheim Int Compuestos antiproliferativos.
ES2598178T5 (es) 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
US20110293750A1 (en) 2008-11-11 2011-12-01 Yale University Activated wnt-beta-catenin signaling in melanoma
ES2422263T3 (es) 2008-12-19 2013-09-10 Nerviano Medical Sciences Srl Pirazoles bicíclicos como inhibidores de la proteinquinasa
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
JP5789602B2 (ja) 2009-06-15 2015-10-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルピロロピリジノン誘導体、これらの製造のための方法およびキナーゼ阻害剤としてのこれらの使用
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2011092088A1 (en) 2010-01-27 2011-08-04 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
EP2560966B1 (en) 2010-03-30 2021-01-06 Verseon International Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
JP5938038B2 (ja) 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
HUE032100T2 (en) 2011-03-21 2017-08-28 Valcuria Ab A pharmaceutical composition comprising an HDAC inhibitor and a steroid and its use
US20140113919A1 (en) 2011-06-14 2014-04-24 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
DK2782557T3 (en) 2011-11-23 2018-12-10 Array Biopharma Inc PHARMACEUTICAL FORMULATIONS
RU2015121367A (ru) 2012-11-08 2017-01-10 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pizzolato, N. et al., Theory in Biosciences, 2011, Vol. 130, No. 3, pages 203-210. *
Tomasetti, C. et al., Mathematical Biosciences and Engineering, 2010, Vol. 7, No. 4, pages 905-918. *

Also Published As

Publication number Publication date
HK1198920A1 (en) 2015-06-19
AU2012335663A1 (en) 2014-05-29
RU2014117707A (ru) 2015-12-20
CN103917236A (zh) 2014-07-09
CA2855243C (en) 2020-04-14
US20140275136A1 (en) 2014-09-18
RU2622015C2 (ru) 2017-06-08
EP2776037B1 (en) 2019-01-09
BR112014011223A8 (pt) 2023-01-31
MX354725B (es) 2018-03-16
BR112014011223A2 (pt) 2017-05-09
EP2776037A1 (en) 2014-09-17
CN108542906A (zh) 2018-09-18
CA2855243A1 (en) 2013-05-16
JP2014533272A (ja) 2014-12-11
JP6150813B2 (ja) 2017-06-21
US11007194B2 (en) 2021-05-18
WO2013070996A1 (en) 2013-05-16
MX2014005726A (es) 2014-05-28

Similar Documents

Publication Publication Date Title
AU2012335663B2 (en) Method of treating a proliferative disease
Sun et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
Furukawa Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside
Tsimberidou Targeted therapy in cancer
Tanaka et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations
Sarkisian et al. MEK inhibitors for the treatment of NRAS mutant melanoma
Martinelli et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells
Luke et al. The biology and clinical development of MEK inhibitors for cancer
von Euw et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
Patyna et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
Corrado et al. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis
Guillaumond et al. Pancreatic tumor cell metabolism: focus on glycolysis and its connected metabolic pathways
Stein et al. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma
Girotti et al. Deja Vu: EGF receptors drive resistance to BRAF inhibitors
Rajendra et al. Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
Imyanitov et al. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation
JP2017521474A (ja) 組み合わせ療法
Suryavanshi et al. MEK inhibitors in oncology: a patent review and update (2016–present)
Ding et al. Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2
Francis et al. The current status of targeted therapy for non‐small cell lung cancer
Martin-Liberal et al. Prospects for MEK inhibitors for treating cancer
HK1198920B (en) Method of treating a proliferative disease
Crane et al. The therapeutic promise of anti-cancer drugs against the Ras/Raf/MEK/ERK pathway
Czejka et al. Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ARRAY BIOPHARMA, INC.

Free format text: FORMER OWNER(S): NOVARTIS AG

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO ARRAY BIOPHARMA INC.